Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Public ClinicalTrials.gov record NCT06170788. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.
Study identification
- NCT ID
- NCT06170788
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 614 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab tirumotecan Biological
- Pembrolizumab Biological
- Supportive care measures Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2023 (Actual)
- Primary completion
- Jan 25, 2028 (Estimated)
- Completion
- May 27, 2030 (Estimated)
- Last update posted
- Oct 15, 2026
2023 – 2030
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona - Phoenix ( Site 0147) | Phoenix | Arizona | 85054 | Recruiting |
| Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) | Burbank | California | 91505 | Recruiting |
| Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) | Grand Junction | Colorado | 81501 | Recruiting |
| Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) | Jacksonville | Florida | 32224 | Recruiting |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106) | Marietta | Georgia | 30060 | Completed |
| The University of Louisville, James Graham Brown Cancer Center ( Site 0121) | Louisville | Kentucky | 40202 | Completed |
| New England Cancer Specialists ( Site 0143) | Westbrook | Maine | 04092 | Recruiting |
| University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144) | Worcester | Massachusetts | 01655 | Completed |
| Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115) | Minneapolis | Minnesota | 55407 | Recruiting |
| Mayo Clinic - Rochester ( Site 0148) | Rochester | Minnesota | 55905 | Recruiting |
| Hattiesburg Clinic Hematology/Oncology ( Site 0104) | Hattiesburg | Mississippi | 39401 | Recruiting |
| Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134) | Reno | Nevada | 89502 | Recruiting |
| University Hospitals Cleveland Medical Center ( Site 0119) | Cleveland | Ohio | 44106 | Completed |
| Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117) | Corvallis | Oregon | 97330 | Recruiting |
| Oncology Consultants P.A. ( Site 0129) | Houston | Texas | 77030 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 205 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06170788, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06170788 live on ClinicalTrials.gov.